The therapeutic potential of 139H2 therefore lies in targeting the characteristic overexpression of MUC1 in tumor cells, not the aberrant MUC1 glycosylation that is commonly described in MUC1-overexpressing cancers. This evidence concerns the gene MUC1 and neoplasm.